{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:19:19Z","timestamp":1789165159046,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Bristol Myers Squibb"},{"DOI":"10.13039\/501100013170","name":"Ono Pharmaceutical Co., Ltd.","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100013170","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03763-5","type":"journal-article","created":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T10:06:09Z","timestamp":1789121169000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evolution of Real-World Treatment Patterns over Time in Patients with HER2-Negative Advanced Gastric Cancer: A Retrospective Database Cohort Study from Japan"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9714-231X","authenticated-orcid":false,"given":"Shuichi","family":"Hironaka","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4331-6598","authenticated-orcid":false,"given":"Yuya","family":"Kimijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Shinno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Nishiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-9517","authenticated-orcid":false,"given":"Yorifumi","family":"Kikko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuko","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-9482","authenticated-orcid":false,"given":"Tsunehisa","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2366-0960","authenticated-orcid":false,"given":"Bruno Casaes","family":"Teixeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1936-9484","authenticated-orcid":false,"given":"Takaki","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,11]]},"reference":[{"key":"3763_CR1","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74:229\u201363.","journal-title":"CA Cancer J Clin"},{"key":"3763_CR2","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1093\/annonc\/mdz178","volume":"30","author":"G Carioli","year":"2019","unstructured":"Carioli G, Malvezzi M, Bertuccio P, et al. Cancer mortality in the elderly in 11 countries worldwide, 1970-2015. Ann Oncol. 2019;30:1344\u201355.","journal-title":"Ann Oncol"},{"key":"3763_CR3","unstructured":"National Cancer Center. Cancer statistics in Japan 2026. 2026. https:\/\/ganjoho.jp\/public\/qa_links\/report\/statistics\/2026_en.html. Accessed 12 May\u00a02026."},{"key":"3763_CR4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1007\/s10120-013-0297-z","volume":"17","author":"F Lordick","year":"2014","unstructured":"Lordick F, Lorenzen S, Yamada Y, Ilson D. Optimal chemotherapy for advanced gastric cancer: is there a global consensus? Gastric Cancer. 2014;17:213\u201325.","journal-title":"Gastric Cancer"},{"key":"3763_CR5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase\u00a0III trial. Lancet Oncol. 2008;9:215\u201321.","journal-title":"Lancet Oncol"},{"key":"3763_CR6","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (3rd edition) [in Japanese]. 2010. https:\/\/www.jgca.jp\/guideline\/third\/index.html. Accessed 29 Oct 2025."},{"key":"3763_CR7","unstructured":"Pharmaceuticals and Medical Devices Agency. Xeloda (capecitabine) tablets: prescribing information [in Japanese]. 2011. https:\/\/www.pmda.go.jp\/files\/000148620.pdf. Accessed 1 Oct 2025."},{"key":"3763_CR8","unstructured":"Japanese Gastric Cancer Association. Overview of the G-SOX study and comments from the Japan Gastric Cancer Association Guidelines Committee on oral fluoropyrimidine + oxaliplatin combination therapy [in Japanese]. 2015. https:\/\/www.jgca.jp\/wp-content\/uploads\/2023\/08\/ohpsokuhou20150709.pdf. Accessed 1 Oct 2025."},{"key":"3763_CR9","unstructured":"Pharmaceuticals and Medical Devices Agency. Elplat (oxaliplatin) intravenous infusion: prescribing information [in Japanese] 2015. https:\/\/www.pmda.go.jp\/files\/000204095.pdf. Accessed 1 Oct 2025."},{"key":"3763_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K, et al. Phase\u00a0III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol. 2015;26:141\u20138.","journal-title":"Ann Oncol"},{"key":"3763_CR11","unstructured":"Pharmaceuticals and Medical Devices Agency. List of approved drugs: April 2004 to March 2025. 2025. https:\/\/www.pmda.go.jp\/english\/review-services\/reviews\/approved-information\/drugs\/0002.html. Accessed 15 Oct 2025."},{"key":"3763_CR12","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/S0140-6736(13)61719-5","volume":"383","author":"CS Fuchs","year":"2014","unstructured":"Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase\u00a03 trial. Lancet. 2014;383:31\u20139.","journal-title":"Lancet"},{"key":"3763_CR13","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1016\/S1470-2045(14)70420-6","volume":"15","author":"H Wilke","year":"2014","unstructured":"Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase\u00a03 trial. Lancet Oncol. 2014;15:1224\u201335.","journal-title":"Lancet Oncol"},{"key":"3763_CR14","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"3763_CR15","unstructured":"Bristol-Myers Squibb. Japan Ministry of Health, Labor and Welfare approves Opdivo (nivolumab) for the treatment of patients with unresectable advanced or recurrent gastric cancer which has progressed after chemotherapy. 2017. https:\/\/news.bms.com\/news\/details\/2017\/Japan-Ministry-of-Health-Labor-and-Welfare-Approves-Opdivo-nivolumab-for-the-Treatment-of-Patients-with-Unresectable-Advanced-or-Recurrent-Gastric-Cancer-Which-Has-Progressed-After-Chemotherapy\/default.aspx. Accessed 15 Oct 2025."},{"key":"3763_CR16","unstructured":"Taiho Pharmaceutical Co., Ltd. Taiho Pharmaceutical obtains additional indication of gastric cancer in Japan for its anticancer agent Lonsurf\u00ae. 2019. https:\/\/www.taiho.co.jp\/en\/release\/2019\/20190822.html. Accessed 15 Oct 2025."},{"key":"3763_CR17","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Oncol. 2018;19:1437\u201348.","journal-title":"Lancet Oncol"},{"key":"3763_CR18","unstructured":"Ono Pharmaceutical Co., Ltd. ONO receives approval of Opdivo\u00ae (nivolumab) for expanded use for two indications in Japan. 2021. https:\/\/www.ono-pharma.com\/en\/news\/20211125.html. Accessed 15 Oct 2025."},{"key":"3763_CR19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase\u00a03 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"3763_CR20","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH, et al. Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase\u00a03 trial. Lancet Oncol. 2022;23:234\u201347.","journal-title":"Lancet Oncol"},{"key":"3763_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1007\/s10120-011-0042-4","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2010 (3rd version). Gastric Cancer. 2011;14:113\u201323.","journal-title":"Gastric Cancer"},{"key":"3763_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-016-0622-4","volume":"20","author":"Japanese Gastric Cancer Association","year":"2017","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2014 (4th edition). Gastric Cancer. 2017;20:1\u201319.","journal-title":"Gastric Cancer"},{"key":"3763_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-020-01042-y","volume":"24","author":"Japanese Gastric Cancer Association","year":"2021","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24:1\u201321.","journal-title":"Gastric Cancer"},{"key":"3763_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10120-022-01331-8","volume":"26","author":"Japanese Gastric Cancer Association","year":"2023","unstructured":"Japanese Gastric Cancer Association. Japanese gastric cancer treatment guidelines 2021 (6th edition). Gastric Cancer. 2023;26:1\u201325.","journal-title":"Gastric Cancer"},{"key":"3763_CR25","doi-asserted-by":"publisher","first-page":"175883592412294","DOI":"10.1177\/17588359241229428","volume":"16","author":"T Ogata","year":"2024","unstructured":"Ogata T, Narita Y, Oze I, et al. Chronological improvement of survival in patients with advanced gastric cancer over 15\u00a0years. Ther Adv Med Oncol. 2024;16:17588359241229428.","journal-title":"Ther Adv Med Oncol"},{"key":"3763_CR26","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1007\/s10120-025-01641-7","volume":"28","author":"S Kadowaki","year":"2025","unstructured":"Kadowaki S, Otsuka T, Minashi K, et al. An observational study of the effectiveness and safety of nivolumab plus chemotherapy for untreated advanced or recurrent gastric cancer in Japanese real-world settings: the G-KNIGHT study. Gastric Cancer. 2025;28:955\u201367.","journal-title":"Gastric Cancer"},{"key":"3763_CR27","doi-asserted-by":"publisher","first-page":"100072","DOI":"10.1016\/j.esmogo.2024.100072","volume":"5","author":"K Shimozaki","year":"2024","unstructured":"Shimozaki K, Fukuda K, Ooki A, et al. Safety and efficacy of first-line nivolumab plus chemotherapy for HER2-negative advanced gastric or gastroesophageal junction adenocarcinoma: real-world data analysis. ESMO Gastrointest Oncol. 2024;5:100072.","journal-title":"ESMO Gastrointest Oncol"},{"key":"3763_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2188\/jea.JE20200288","volume":"31","author":"K Hayashida","year":"2021","unstructured":"Hayashida K, Murakami G, Matsuda S, Fushimi K. History and profile of diagnosis procedure combination (DPC): development of a real data collection system for acute inpatient care in Japan. J Epidemiol. 2021;31:1\u201311.","journal-title":"J Epidemiol"},{"key":"3763_CR29","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jgo.2021.12.017","volume":"13","author":"E Otto","year":"2022","unstructured":"Otto E, Culakova E, Meng S, et al. Overview of Sankey flow diagrams: focusing on symptom trajectories in older adults with advanced cancer. J Geriatr Oncol. 2022;13:742\u20136.","journal-title":"J Geriatr Oncol"},{"key":"3763_CR30","unstructured":"National Cancer Center. Hospital-based cancer registry case statistics. 2026. https:\/\/ganjoho.jp\/public\/qa_links\/report\/hosp_c\/hosp_c_registry.html. Accessed 14 May\u00a02026."},{"key":"3763_CR31","unstructured":"National Cancer Center. Cancer Statistics in Japan. 2026. https:\/\/ganjoho.jp\/reg_stat\/statistics\/data\/dl\/en.html. Accessed 14 May\u00a02026."},{"key":"3763_CR32","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3390\/jcm13092524","volume":"13","author":"Y Xing","year":"2024","unstructured":"Xing Y, Hosaka H, Moki F, et al. Gender differences in patients with gastric adenocarcinoma. J Clin Med. 2024;13:2524.","journal-title":"J Clin Med"},{"key":"3763_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2026.02.003","author":"YY Janjigian","year":"2026","unstructured":"Janjigian YY, Shitara K, Ajani JA, et al. Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649. Ann Oncol. 2026. https:\/\/doi.org\/10.1016\/j.annonc.2026.02.003.","journal-title":"Ann Oncol"},{"key":"3763_CR34","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1007\/s12325-021-01931-3","volume":"39","author":"Y Komatsu","year":"2022","unstructured":"Komatsu Y, Hironaka S, Tanizawa Y, Cai Z, Piao Y, Boku N. Treatment pattern for advanced gastric cancer in Japan and factors associated with sequential treatment: a retrospective administrative claims database study. Adv Ther. 2022;39:296\u2013313.","journal-title":"Adv Ther"},{"key":"3763_CR35","unstructured":"Cancer Society Guidelines Committee. Summary of the CheckMate649 trial, ATTRACTION-4 trial, and HER2-negative unresectable cancer. 2021. https:\/\/www.jgca.jp\/wp-content\/uploads\/2023\/08\/news202112_1.pdf. Accessed 11 June 2026."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03763-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03763-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:01:44Z","timestamp":1789164104000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03763-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,11]]},"references-count":35,"alternative-id":["3763"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03763-5","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,11]]},"assertion":[{"value":"5 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shuichi Hironaka has received consulting fees from Astellas and BeOne Medicines (formerly BeiGene); and has received honoraria from Astellas, AstraZeneca, Bayer, Bristol Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daichii Sankyo, Eli Lilly, Merck Biopharma, MSD, Novartis, Ono Pharmaceutical Co., Ltd., Servier, Taiho Pharmaceutical Co., Ltd, and Takeda Pharmaceutical. Yuya Kimijima, Yorifumi Kikko, and Tsunehisa Yamamoto are employees of Bristol Myers Squibb. Yusuke Shinno, Eiji Nishiyama, and Yuko Matsuda are employees of Ono Pharmaceutical Co., Ltd. Bruno Casaes Teixeira is an employee of and holds stock or stock options in Bristol Myers Squibb. Takaki Yoshikawa has received honoraria from Astellas, AstraZeneca, Bristol-Myers Squibb, Chugai Pharmaceutical Co., Ltd, Daiichi Sankyo, Intuitive Surgical, Johnson & Johnson, Medtronic, Olympus, Ono Pharmaceutical Co., Ltd., and Taiho Pharmaceutical; has received research funding from Eli Lilly; and has acted in a consulting or advisory role for MSD and Terumo Corporation. Tsunehisa Yamamoto\u2019s affiliation has changed since the completion of the manuscript. The current affiliation is now Heartseed Inc., Tokyo, Japan.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was conducted in accordance with International Society for Pharmacoepidemiology (ISPE) Guidelines for Good Pharmacoepidemiology Practices (GPP) and applicable regulatory requirements. Institutional review board approval was not required because the Medical Data Vision (MDV) data sources have undergone extensive ethical review and approval, and the database is compliant with regulations associated with scientific and medical research involving human subjects, including the use of patient-level data, in Japan. Informed consent from patients was also not required because data elements in the MDV database have been de-identified. Data were processed as anonymized information, with personal identifiers masked. The use and analysis of data from the database is considered to be secondary use of the data and is compliant with the Act on the Protection of Personal Information (available here:\n                      \n                      ). The MDV database used in this study was accessed and used under a data license\/use agreement with MDV Co., Ltd. (Tokyo, Japan).","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}